Chemomab Therapeutics Ltd. (CMMB)

NCM – Real vaqt narxi. Valyuta: USD

1.59

+0.02 (1.27%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

1.59

+0.00 (0.32%)

Bozordan keyin: Jun 26, 2026, 4:04 PM EDT

14.05.2026

Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

—New C linical and Translational Data Presented at Major Medical Meetings Further Confirms the Disease-Modifying Potential of Nebokitug in Primary Sclerosing Cholangitis and Suggests Possible Additional Benefit in PSC Patients with Co-Existing IBD— —Company Continues to Advance Multiple Partnering Options for Nebokitug— TEL AVIV, Israel, May 14, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the first quarter ended March 31, 2026, and provided a corporate update.

19.03.2026

Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update

2025 was a critical year for Chemomab and nebokitug. Partnering discussions continue to advance along with preparations to launch the PSC Phase 3 trial.

17.02.2026

Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

TEL AVIV, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that CEO Dr. Adi Mor and other members of its senior management team will deliver a corporate presentation and participate in one-on-one investor meetings at the virtual Oppenheimer 36 th Annual Healthcare Life Sciences Conference on February 26, 2026.

02.12.2025

Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology

— New Peer-Reviewed Publication Highlights Phase 2 SPRING Trial Data Supporting the Disease Modifying Potential of Nebokitug in PSC and Supports Advancement to a P hase 3 Registration Trial — TEL AVIV, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the results of its Phase 2 SPRING trial assessing nebokitug in patients with primary sclerosing cholangitis (PSC) were published in the current issue of the American Journal of Gastroenterology.1 The study showed that nebokitug was generally safe and well tolerated in patients with PSC for up to 48 weeks of treatment.

24.11.2025

Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit

TEL AVIV, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that co-founder and CEO Adi Mor, PhD, will participate in Oppenheimer's Movers in Rare Disease Summit on Thursday, December 11, 2025, at the Sofitel Hotel in New York City.

20.11.2025

Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

—Nebokitug PSC Phase 3 Design Near Completion Following Positive FDA Feedback— —Regulatory Alignment Advances, with EMA Guidance Supporting a Single Nebokitug Phase 3 Registration Trial Using a Clinical Event Composite Endpoint — —Phase 2 SPRING Trial OLE Data Showing Favorable Safety and Consistent Improvements in Key Biomarkers in PSC Patients Treated with Nebokitug for Up to 48 Weeks Presented at AASLD 2025 — — New Clinical Data Presented at AASLD 2025 Provides Insights on Nebokitug's Direct Macrophage-Mediated Mechanisms that Are Relevant to Halting or Slowing PSC Disease Progression— —Multiple Partnering Options for Supporting the Nebokitug Phase 3 Program Continue to Advance— —Cash Runway Expected through End of Fourth Quarter of 2026— TEL AVIV, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the third quarter ended September 30, 2025, and provided a corporate update.

06.11.2025

Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis

Chemomab announced three presentations "of distinction" at AASLD The Liver Meeting® 2025 featuring clinical data from the nebokitug Phase 2 trial in PSC.

Videolar

No Data

There is no data to display

Press-relizlar

14.05.2026

Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

19.03.2026

Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update

2025 was a critical year for Chemomab and nebokitug. Partnering discussions continue to advance along with preparations to launch the PSC Phase 3 trial.

17.02.2026

Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

02.12.2025

Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology

Chemomab Therapeutics Ltd. (CMMB)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Chemomab Therapeutics Ltd. (CMMB)

Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update

Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology

Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit

Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis

Videolar

No Data

Press-relizlar

Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update

Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology

Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update

Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology

Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit

Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis

Videolar

No Data

Press-relizlar

Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update

Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology

Search stocks

Chemomab Therapeutics Ltd. (CMMB)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Chemomab Therapeutics Ltd. (CMMB)

Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update

Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology

Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit

Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis

Videolar

No Data

Press-relizlar

Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update

Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology

Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update

Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology

Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit

Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis

Videolar

No Data

Press-relizlar

Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update

Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology